

18 June 2026

Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")

Proactive One2One Investor Forum

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that it will be presenting at the Proactive One2One Investor Forum (the "Forum") in London on Wednesday 24 June 2026 at 6.00 pm.

The Forum will be hosted at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB.

Coiled Therapeutics' Chairman Sotirios Stergiopoulos will be delivering a presentation, which will be made available on the Company's website: www.coiledplc.com

In order to register for the event, please use the following link:
https://www.proactiveinvestors.co.uk/register/event_details/470

-Ends-

Enquiries:

Coiled Therapeutics plc

Sotirios Stergiopoulos (Chairman)
Sridhar Vempati (CEO)

Via Burson
Buchanan

**SP Angel Corporate Finance LLP (Nominated Adviser
and Joint Broker)**

+44 (0)20 3470 0470

David Hignell / Adam Cowl / Devik Mehta (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Shard Capital Partners LLP (Joint Broker)

+44 (0)20 4530 6926

Damon Heath

CPS Capital Group Pty Ltd (Joint Broker)

+61 (0)8 9223 2222

Jason Peterson / David Valentino

Burson Buchanan (Public Relations)

+44 (0)20 7466 5000

Henry Harrison Topham / Jamie Hooper / Toto Berger

Harbor Access (US Investor Relations)

+1 475 477 9404

Matt Kelly / Jonathan Paterson

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL, OTCQB: COTXF) is an AIM-listed, clinical-stage oncology company focused on developing innovative precision therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is

also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, a key differentiator that may enable treatment of both primary brain tumours and brain metastases, areas of significant unmet medical need. Preclinical and early clinical observations support further evaluation of the programme's potential across multiple tumour types.

AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study in the United States. Early clinical observations have demonstrated encouraging anti-tumour activity and a favourable safety profile, with the Company planning to initiate dose expansion cohorts in selected indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com and follow us on [LinkedIn](#).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUNOSRNNUNAAR